000849853 001__ 849853
000849853 005__ 20210129234319.0
000849853 0247_ $$2doi$$a10.1097/WCO.0000000000000574
000849853 0247_ $$2ISSN$$a1350-7540
000849853 0247_ $$2ISSN$$a1473-6551
000849853 0247_ $$2pmid$$apmid:29952832
000849853 0247_ $$2WOS$$aWOS:000455659300002
000849853 0247_ $$2Handle$$a2128/21908
000849853 0247_ $$2altmetric$$aaltmetric:44679896
000849853 037__ $$aFZJ-2018-03955
000849853 082__ $$a610
000849853 1001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b0$$eCorresponding author
000849853 245__ $$aUpdate on amino acid PET of brain tumours
000849853 260__ $$aLondon$$bLippincott Williams & Wilkins$$c2018
000849853 3367_ $$2DRIVER$$aarticle
000849853 3367_ $$2DataCite$$aOutput Types/Journal article
000849853 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1547048282_3109
000849853 3367_ $$2BibTeX$$aARTICLE
000849853 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000849853 3367_ $$00$$2EndNote$$aJournal Article
000849853 520__ $$aPurpose of review The aim of this study was to give an update on the emerging role of PET using radiolabelled amino acids in the diagnostic workup and management of patients with cerebral gliomas and brain metastases.Recent findings Numerous studies have demonstrated the potential of PET using radiolabelled amino acids for differential diagnosis of brain tumours, delineation of tumour extent for treatment planning and biopsy guidance, differentiation between tumour progression and recurrence versus treatment-related changes, and for monitoring of therapy. The Response Assessment in Neuro-Oncology (RANO) working group – an international effort to develop new standardized response criteria for clinical trials in brain tumours – has recently recommended the use of amino acid PET imaging for brain tumour management in addition to MRI at every stage of disease. With the introduction of F-18 labelled amino acids, a broader clinical application has become possible, but is still hampered by the lack of regulatory approval and of reimbursement in many countries.Summary PET using radiolabelled amino acids is a rapidly evolving method that can significantly enhance the diagnostic value of MRI in brain tumours. Current developments suggest that this imaging technique will become an indispensable tool in neuro-oncological centres in the near future.
000849853 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000849853 588__ $$aDataset connected to CrossRef
000849853 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b1
000849853 773__ $$0PERI:(DE-600)2026967-5$$a10.1097/WCO.0000000000000574$$gVol. 31, no. 4, p. 354 - 361$$n4$$p354 - 361$$tCurrent opinion in neurology$$v31$$x1350-7540$$y2018
000849853 8564_ $$uhttps://juser.fz-juelich.de/record/849853/files/Langen_Post%20Print_2018_%20Curr%20Opin%20Neurol_Update%20on%20amino%20acid%20PET%20of%20brain%20tumours.pdf$$yPublished on 2018-08-01. Available in OpenAccess from 2019-08-01.
000849853 8564_ $$uhttps://juser.fz-juelich.de/record/849853/files/Langen_Post%20Print_2018_%20Curr%20Opin%20Neurol_Update%20on%20amino%20acid%20PET%20of%20brain%20tumours.pdf?subformat=pdfa$$xpdfa$$yPublished on 2018-08-01. Available in OpenAccess from 2019-08-01.
000849853 909CO $$ooai:juser.fz-juelich.de:849853$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000849853 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b0$$kFZJ
000849853 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b1$$kFZJ
000849853 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000849853 9141_ $$y2018
000849853 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000849853 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000849853 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000849853 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR OPIN NEUROL : 2015
000849853 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000849853 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000849853 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000849853 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000849853 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000849853 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000849853 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000849853 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000849853 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000849853 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000849853 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000849853 920__ $$lyes
000849853 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000849853 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x1
000849853 980__ $$ajournal
000849853 980__ $$aVDB
000849853 980__ $$aUNRESTRICTED
000849853 980__ $$aI:(DE-Juel1)INM-4-20090406
000849853 980__ $$aI:(DE-Juel1)INM-3-20090406
000849853 9801_ $$aFullTexts